News /

Sinn Féin has its eyes on the prize

Sinn Féin has its eyes on the prize

Independent News & Media has nothing to fear from Sinn Féin’s war on the establishment, but independent politicians do

Watchdog extends  its inquiry into CapVest acquisition

Watchdog extends its inquiry into CapVest acquisition

Nama to apply for planning permission in ‘Google quarter’

Nama to apply for planning permission in ‘Google quarter’

Revenue boost for Irish football investment funds  More than €6m reaped from player moves in 2013

Revenue boost for Irish football investment funds More than €6m reaped from player moves in 2013

French finance minister is keeping an eye on patent box

French finance minister is keeping an eye on patent box

Irish trader investigated in Swiss foreign exchange scandal

Irish trader investigated in Swiss foreign exchange scandal

Funding fast-tracked for first tranche of social housing

Funding fast-tracked for first tranche of social housing

Is mother’s ruin back? Artisan distillers cooking up a gin revival

Is mother’s ruin back? Artisan distillers cooking up a gin revival

Kelly ignored expert advice and gave €4m for greenway during by-election

Kelly ignored expert advice and gave €4m for greenway during by-election

String of recommended routes ignored by minister in key funding decisions

The property tax poison pill

The property tax poison pill

Many will be rejoicing at the rise in property prices, but there is a catch – higher home values mean bigger property tax bills, writes Eamon Quinn

‘Novel approach’ to liquidation of credit union

‘Novel approach’ to liquidation of credit union

Former Finance boss Moran reveals details of crisis years

Former Finance boss Moran reveals details of crisis years

NPRF has more than €2bn to invest in Irish projects

NPRF has more than €2bn to invest in Irish projects

Capital’s luxury hotels say there’s no room at the inn

Capital’s luxury hotels say there’s no room at the inn

Reinvention for pharma chief with new $40m US venture

Reinvention for pharma chief with new $40m US venture